Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Lower DHEA-S level ups risk for heart failure, death in older adults

10 Nov 2020

Low levels of dehydroepiandrosterone-sulfate (DHEA-S) may increase the risk for heart failure (HF) and mortality but not coronary heart disease (CHD), a study has found.

The investigators measured DHEA-S in stored plasma from visits 4 (1996–1998) and 5 (2011–2013) of the Atherosclerosis Risk in Communities Study. The follow-up for incident events was 18 years for DHEA-S level and 5.5 years for DHEA-S change.

A total of 8,143 individuals without prevalent cardiovascular disease (mean age, 63 years) in a general community setting were included in this study. The investigators then assessed the associations between DHEA-S and incident HF hospitalization, CHD, or mortality, and that between 15-year change in DHEA-S (n=3,706) and cardiovascular events.

DHEA-S levels below the 15th sex-specific percentile of the study population (men: 55.4 µg/dL; women: 27.4 µg/dL) correlated with a higher risk for HF hospitalization (men: hazard ratio [HR], 1.30, 95 percent confidence interval [CI], 1.07–1.58; women: HR, 1.42, 95 percent CI, 1.13–1.79).

Furthermore, DHEA-S below the 25th sex-specific percentile (men: 70.0 µg/dL; women: 37.1 µg/dL) correlated with increased mortality risk (men: HR, 1.12, 95 percent CI, 1.01–1.25; women: HR, 1.19, 95 percent CI, 1.03–1.37).

Greater percentage decrease in DHEA-S further increased the risk for HF hospitalization in men (HR, 1.94, 95 percent CI, 1.11–3.39) but not in women. On the other hand, low DHEA-S and change in DHEA-S did not correlate with incident CHD.

“Further investigation is warranted to evaluate mechanisms underlying these associations,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).